anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
<P>PROBLEM TO BE SOLVED: To develop a material and a related method for manufacturing an intraluminal stent for providing a designer of a device with an opportunity to design the device for a specific application by engineering technologies.  <P>SOLUTION: A biocompatible material can be designed as various kinds of medical devices which can be implanted, including the intraluminal stent. All the devices including the stent can be manufactured using polymeric materials. The stent can be balloon-expansible or self-expansible. Some desired performance characteristics can be obtained by selectively and mechanically deforming polymers and orienting polymer chains.  <P>COPYRIGHT: (C)2007,JPO&INPIT
The two types of craniopharyngioma, adamantinomatous (ACP) and papillary (PCP), are clinically relevant tumours in children and adults. Although the biology of primary craniopharyngioma is starting to be unravelled, little is known about the biology of recurrence. To fill this gap in knowledge, we have analysed through methylation array, RNA sequencing and pERK1/2 immunohistochemistry a cohort of paired primary and recurrent samples (32 samples from 14 cases of ACP and 4 cases of PCP). We show the presence of copy number alterations and clonal evolution across recurrence in 6 cases of ACP, and analysis of additional whole genome sequencing data from the Children's Brain Tumour Network confirms chromosomal arm copy number changes in at least 7/67 ACP cases. The activation of the MAPK/ERK pathway, a feature previously shown in primary ACP, is observed in all but one recurrent cases of ACP. The only ACP without MAPK activation is an aggressive case of recurrent malignant human craniopharyngioma harbouring a CTNNB1 mutation and loss of TP53. Providing support for a functional role of this TP53 mutation, we show that Trp53 loss in a murine model of ACP results in aggressive tumours and reduced mouse survival. Finally, we characterise the tumour immune infiltrate showing differences in the cellular composition and spatial distribution between ACP and PCP. Together, these analyses have revealed novel insights into recurrent craniopharyngioma and provided preclinical evidence supporting the evaluation of MAPK pathway inhibitors and immunomodulatory approaches in clinical trials in against recurrent ACP.
The present invention relates to a Neisser's coccus vaccine composite, the preparation of the composite and the application of the composite in medicine. More specifically, the present invention relates to a method of producing a novel engineered meningococcus strain which is more suitable for the production of the adventitial vesicle (or blain) vaccine of Neisser's coccus, particularly meningococci. Based on the application of the novel LOS subunit or meningococcal adventitial vesicle (or blain) vaccine, a favorable method and a vaccine product are also described, and the LOS subunit or meningococcal adventitial vesicle (or blain) vaccine can be more safely and effectively used on a human subject. Specifically, the present invention describes gene-downregulated combinations, such as PorA and OpA, PorA and OpC, OpA and OpC, PorA and OpA and OpC. Alternatively or additionally, the present invention indicates that lgtB<-> is the optimal mutation which ensures that L3 and / or L2 LOS can be effectively and safely used in the Neisser's coccus vaccine composite. The present invention also describes a blain vaccine coming from the lgtB<-> and the meningococcal mutant strain and a favorable method of preparing a blain preparation, and wherein, the LOS is maintained as an important antigen.
For the OMM treatment group, an osteopathic manipulative treatment protocol will be applied to the cranial, cervical, thoracic, and ribcage regions. OMM procedures performed on the treatment group willconsist of 1. suboccipital decompression/release, 2. base spread, 3. occipitoatlantal (OA) decompression, 4. venous sinus drainage, 5. compression of the fourth ventricle, 6. cervical myofascial (unilateralperpendicular stretch), 7. thoracic inlet release (direct or indirect), 8. Bilateral rib raising, 9. thoracoabdominal diaphragm doming (direct technique), and 10. pedal pump (Dalrymple lymphatic pump). All aforementioned techniques are based on the protocol from Foundations of Osteopathic Medicine.
Patients receive olaparib PO BID on days 1-28 and abemaciclib PO BID on days 8-28 of cycle 1 and days 1-28 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood and undergo tumor biopsy on study.
Pulmonary fibrosis is a progressive lung condition characterized by the excessive activation of myofibroblasts. Transforming growth factor beta 1 (TGFβ1) plays a crucial role in the differentiation of fibroblasts into myofibroblasts. In addition, toll-like receptor 2 (TLR2), known for its role in immune responses, contributes to pulmonary fibrosis by promoting myofibroblast differentiation. However, the interplay between TGFβ1 and TLR2 signaling pathways in myofibroblast differentiation has remained elusive. In the present study, we investigated the involvement of TLR2 in TGFβ1-induced fibroblast differentiation into myofibroblasts using IMR-90 human pulmonary fibroblasts as a model cell line. We found that TLR2 activation induced myofibroblast differentiation by enhancing the expression of early growth response 1 (EGR1) via the mitogen-activated protein kinase (MAPK) signaling pathway. Elevated EGR1 levels were detected in the lung tissues of a bleomycin (BLM)-induced mouse model of pulmonary fibrosis. Moreover, the administration of tomaralimab, an antagonistic anti-TLR2 antibody, reduced the EGR1 expression and collagen deposition. Altogether, targeting the TLR2-EGR1 pathway could be a promising therapeutic approach for pulmonary fibrosis by blocking TGFβ1-induced myofibroblast differentiation.
Extensor mechanism (EM) disruption is a rare but severe complication of total knee arthroplasty (TKA) that can greatly impair function. Treatment options for chronic patella tendon ruptures include primary repair, autograft augmentation, and reconstruction with allograft or synthetic material. Despite various techniques, failures can occur, and options for reconstruction after a failed allograft or mesh are limited, especially if the tibial component is well-fixed and cannot be easily removed, and if there is proximal tibial deficiency from a previous failed EM allograft. This case report presents a novel solution for revision EM reconstruction in a 72y.o. female patient with a history of multiple EM failures using an off-label Trabecular Metal Cone-Mesh-Cone (TM CMC) clamshell construct. The surgical procedure involved the removal of a non-viable allograft from the knee joint and the creation of a custom trabecular metal (TM) clamshell construct with a Marlex mesh graft in between the two TM implants. The customized TM cone was designed to cover the deficient anterior tibia and wrap around the ingrown TM cone. The Marlex mesh was cemented between the existing implant and the customized TM cone, and the construct was secured in place with two cancellous screws. The mesh was tunneled between soft tissue to prevent contact with the implant and rotated scar tissue was interposed to prevent abrasion of the mesh on the implant surfaces. The patient tolerated the procedure well and no complications were noted postoperatively. At a follow-up 12 months after the operation the patient remains satisfied with the result.
A composition containing extract of Corydalis turtschaninovii or dehydrocorydaline is provided to prevent and treat dental caries and have antibacterial effect to Streptococci mutans. A composition for preventing and treating dental caries contains 0.1-50 weight% of Corydalis turtschaninovii extract or dehydrocorydaline isolated from the extract. The extract of Corydalis turtschaninovii is obtained with water, low alcohol of C1-C4 or its mixture solvent. The extract of Corydalis turtschaninovii is extracted using lump stem, leaves, and flowers of Corydalis turtschaninovii. The composition is used in a form of tooth paste, oral cleaner or oral spray. A health functional food for preventing and improving tooth caries contains Corydalis turtschaninovii extract or dehydrocoryldaline isolated from the extract as an active ingredient. The health functional food is used in a form of powder, granule, tablet, capsule or beverage.
An analogue peptide that comprises the variable regions of the light or heavy chains of an antibody of a first species selectively binding to a carcinoma antigen has 1 to 46 amino acids of the framework regions per chain substituted with amino acids such as those present in equivalent positions in antibodies of a species other than the first species, or fragments thereof comprising 1 to 3 variable region CDRs per chain and optionally flanking regions thereof of 1 to 10 or more amino acids, alone or with an N-terminal fragment of 1 to 10 or more amino acids, combinations or mixtures thereof. The polypeptide may also comprise an effector agent and/or be glycosylated, and is presented as a composition with a carrier. The analogue peptides are used in diagnostic kits for carcinomas and methods for in vivo imaging and treating a primary or metastasized carcinoma, and in vitro diagnosing a carcinoma, ex vivo purging neoplastic cells from a biological fluid. RNAs and DNAs encode the analogue peptide, and a hybrid vector carrying the nucleotides and transfected cells express the peptides and a method produces the analogue peptide. An anti-idiotype polypeptide comprises polyclonal antibodies raised against an anti-carcinoma antibody or the analogue peptide of this invention, monoclonal antibodies thereof, Fab, Fab', (Fab') 2 , CDR, variable region, or analogues or fragments thereof, combinations thereof with an oligopeptide comprising a TRP trimer, tandem repeats thereof, or combination or mixtures thereof. An anti-idiotype hybrid polypeptide with an effector agent and the anti-idiotype polypeptide, an anti-carcinoma vaccine, an anti-carcinoma vaccination kit, a method of vaccinating against carcinoma and a method of lowering the serum concentration of a circulating antibody or polypeptide are provided.
Kidney epithelial cells have very high energy requirements, which are largely met by fatty acid oxidation. Complex changes in lipid metabolism are observed in patients with kidney disease. Defects in fatty acid oxidation and increased lipid uptake, especially in the context of hyperlipidemia and proteinuria, contribute to this excess lipid build-up and exacerbate kidney disease development. Recent studies have also highlighted the role of increased de novo lipogenesis in kidney fibrosis. The defect in fatty acid oxidation causes energy starvation. Increased lipid uptake, synthesis, and lower fatty acid oxidation can cause toxic lipid build-up, reactive oxygen species generation, and mitochondrial damage. A better understanding of these metabolic processes may open new treatment avenues for kidney diseases by targeting lipid metabolism.
PURPOSE:To provide a titanium oxynitride black pigment which is compatible with resins and has improved dispersibility, heat resistance and safety, by incorporating oxygen and nitrogen in a specified ratio. CONSTITUTION:Titanium dioxide is reacted with ammonia to obtain a black titanium oxynitride powder contg. 4-35wt% oxygen and 2-20wt% nitrogen (with a weight ratio of O/N of 15-0.2). The oxygen and nitrogen contents of the titanium oxynitride vary depending on reaction temp., reaction time, NH3 flow rate, NH3 pressure, etc. Pref. the reaction temp. is 550-950 deg.C. When the reaction temp. is lower than 500 deg.C, the reaction does not progress and the powder is bluish grey, while when it exceeds 950 deg.C, the powder is liable to be sintered and pigment characteristics are lowered. The reaction time varies depending on reaction temp., NH3 flow rate and NH3 pressure. With regard to NH3 pressure, the reaction progresses even under atmospheric pressure and a black powder can be obtd. Hewever, when the reaction is carried out under a pressure of 2-3kg/cm<2>, the reaction rate and the nitrogen content are increased, so that a powder having a high blackness can be obtd.
The application of the RNA binding protein Rbm24 gene in cardiomyopathy and arrhythmia relates to the function and application of the gene. The application of the reagent of Rbm24 gene expression in the preparation of auxiliary diagnosis or prognosis products of cardiomyopathy and arrhythmia; the Rbm24 gene or the Rbm24 protein coded by the Rbm24 gene and the application of the downstream target gene in the medicines for treating the cardiomyopathy or arrhythmia. The Rbm24 gene expression reagent comprises a reagent for detecting the mRNA expression level of the Rbm24 gene and/or a reagent for detecting the protein expression level of the Rbm 24. The reagent for the expression level of the mRNA of the Rbm24 gene comprises a primer used in QPCR and/or a probe. The reagent for detecting the expression level of the Rbm24 protein comprises an antibody aiming at the Rbm24 protein. The antibody comprises a monoclonal antibody, a polyclonal antibody and a site-specific antibody.
Prostate cancer is the second leading cause of cancer death in American men. Hormonal ablation, in the form of medical or surgical castration, is the cornerstone of management for metastatic prostate cancer; however, treatment options for a patient in whom androgen ablation fails are limited. Docetaxel and paclitaxel, taxanes that are cell cycle specific, play a major role in advanced hormone-refractory prostate cancer treatment. In preclinical studies, Xyotax, a conjugate of paclitaxel with enhanced permeability and retention in tumor tissue, has an improved therapeutic profile, with both decreased systemic drug-related toxicities and enhanced efficacy. Xyotax as a single agent has been studied in a broad variety of syngeneic and xenogeneic tumor models. Recognizing that taxanes are active in prostate cancer and preclinical data reports activity with Xyotax in docetaxel and paclitaxel resistant cell lines, there is significant rationale to develop this agent in prostate cancer. Thus, a phase II study is needed to evaluate the antitumor activity in two subsets of hormone refractory prostate cancer patients: those with no prior systemic and those with one prior systemic therapy.
A novel method of geometric isometry based antigen-specific TCR alignment (GIANA) is described herein. GIANA is an antigen-specific TCR clustering method that is able to efficiently handle tens of millions of sequences. GIANA achieved higher sensitivity and precision than all existing methods, and is able to retrieve TCRs specific to known antigens with high accuracy. The ultra-large-scale TCR clustering and fast query of novel samples also enabled a novel reference-based repertoire classification framework. GIANA can also analyze single cell RNA-seq data with TCR regions solved, and it is possible to query TCRs from unknown data against the large database of TCR repertoire samples in the public domain, and provide new insights over shared antigen-specificity. GIANA is applicable to cluster or query large B cell receptor sequencing data as well.
PURPOSE: Dislocation remains 1 of the leading causes of revision after primary total hip arthroplasty (THA) and there is clear evidence the dual-mobility (DM) is used more frequently to minimise this. But in smaller cups, whether the use of DM with smaller 22-mm heads imparts any increased stability compared to standard bearing is unknown; especially when those smaller cups now allow for large single-bearing (SB) heads.
METHODS: 3 primary cup sizes (48 mm, 50 mm, 52 mm) were chosen a priori for modelling. Head sizes trialled for the standard bearing (SB) constructs group were 28-0 mm, 32-0 mm and 36-0 mm against neutral polyethylene liners. In the modular sub-hemispheric DM constructs the inner head sizes for the DM constructs were altered where appropriate (22-0 mm vs. 28-0 mm). Cup position, stem offset, and stem size were standardised.
RESULTS: Both DM constructs outperformed all SB constructs because of a statistically significant jump distance increase (p < 0.001). However, there was no difference in range of motion (ROM) or jump distances between the 22-mm and 28-mm DM inner heads.The ROM angle before impingement between the DM (with 22-mm or 28-mm heads) and SB (with different head sizes where appropriate) showed no statistically significant difference. However, DM constructs presented significantly larger jump distances than SB constructs for both provocative dislocation tests across all 3 cup sizes.Of interest, for 50-mm and 52-mm cup sizes (for which this particular DM construct design can accommodate both 22-mm and 28-mm inner heads), there were no differences in ROM or jump distance between 22-mm versus 28-mm inner heads.
CONCLUSIONS: In this computer-modelling study, DM constructs are advantageous over SB constructs for improving jump distances in clinically provocative positions, but not range of motion angles. Inner head diameter of DM has no effect on stability.
This study aimed to analyze changes in retinol-binding protein 4 (RBP4) levels before and after bariatric surgery in obese individuals. Bariatric surgery is a safe and effective treatment for morbid obesity, impacting molecules like RBP4. A systematic review and meta-analysis of 12 relevant studies were conducted, utilizing databases such as PubMed, Cochrane Central, Web of Science, and Scopus. Significant differences in RBP4, glucose, and BMI levels pre- and post-surgery were observed. Meta-regression analysis explored associations with age, pre-BMI, triglycerides, glucose, and post-insulin levels. Findings suggest RBP4 may improve insulin sensitivity after bariatric surgery, warranting further investigation as a potential pharmacotherapeutic target. These results highlight the importance of understanding RBP4's role in the context of bariatric surgery and its implications for improving metabolic health in obese individuals.
Many Pd patients are non-adherent to their treatments. Because Pd patients are generally over 60 years old, suffer from cognitive disorders, and have complex medication regimens, taking medications as prescribed is a too complex cognitive task for them. It supposes the ability to understand the prescription, to plan and memorize the actions to carry out and to remember them while executing them. As prescriptions are communicated to patients via procedural documents, it should be possible to improve patient's comprehension by using a format suitable for their needs and characteristics. Previous studies with elderly people suggest that the table format is more effective than the textual format. However no study addressed this question with Pd patients.

One-hundred and twenty patients with Parkinson's disease and 120 healthy volunteers participate voluntarily to the study. Their task consists in reading on a touch screen, or on a tablet, two fictive medication prescriptions. One is presented in a table format and the other in a textual format. Each prescription comprises two regular medications (same doses and moments of the day) and two irregular medications (different doses or different moments). For each prescription, participants must fill a virtual pillbox displayed on the screen as prescribed in the prescription. Prescriptions and pillboxes are displayed by a tablet software specifically designed to record in real time all participant's actions and related chronometric data. Half participants perform the task in the " tablet condition ", and the other half in the " touch-screen " condition. In the touch-screen condition an eye-tracker is used to record eye fixations and scanpaths in real time. Once the 2nd pillbox filling is finished a battery of cognitive tests and questionnaires is administered to participants to identify Pd subtypes of impaired performances.

The main hypothesis predicts an effect of the format of prescriptions. More precisely, it consists in two concurrent hypotheses. H1a (the mental model model hypothesis): the table format should facilitate the pillboxes filling in the parkinsonian group and in the healthy volunteer group by facilitating the elaboration of an accurate mental model. H1b (the working memory load hypothesis): because parkinsonian patients are frequently impaired in visuospatial tasks, the tabular format could have no effect or could have a negative effect only in this group. A correlation between cognitive subtypes identified by cluster analyses and task performances is expected. Several secondary hypotheses will be tested.
The mechanistic target of rapamycin complex 1 controls cellular anabolism in response to growth factor signaling and to nutrient sufficiency signaled through the Rag GTPases. Inhibition of mTOR reproducibly extends longevity across eukaryotes. Here we report that mice that endogenously express active mutant variants of RagC exhibit multiple features of parenchymal damage that include senescence, expression of inflammatory molecules, increased myeloid inflammation with extensive features of inflammaging and a ~30% reduction in lifespan. Through bone marrow transplantation experiments, we show that myeloid cells are abnormally activated by signals emanating from dysfunctional RagC-mutant parenchyma, causing neutrophil extravasation that inflicts additional inflammatory damage. Therapeutic suppression of myeloid inflammation in aged RagC-mutant mice attenuates parenchymal damage and extends survival. Together, our findings link mildly increased nutrient signaling to limited lifespan in mammals, and support a two-component process of parenchymal damage and myeloid inflammation that together precipitate a time-dependent organ deterioration that limits longevity.
A system and method for manipulating a virtual object based on intent is described. A reference identifier from a physical object is captured. The reference identifier is communicated via a network to a remote server. The remote server includes virtual object data associated with the reference identifier. The virtual object data is received at the computing device. The virtual image is displayed in a virtual landscape using the virtual object data. In response to relative movement between the computing device and the physical object caused by a user, the virtual image is modified. Brain activity data of the user is received. A state of the virtual object in the virtual landscape is changed based on the brain activity data.